FDA news in pediatrics: January 2025
A recap of the FDA submissions and regulatory decisions in pediatrics from January 2025.
Food Insecurity and the Dangers of Infant Formula Dilution
Phase 3: Delgocitinib improves chronic hand eczema in adolescents
The primary and all key secondary endpoints were met compared to cream vehicle in the phase 3 DELTA TEEN trial.
Demystifying Infant Formula
FDA approves tocilizumab-anoh as biosimilar for multiple diseases
As a biosimilar to Actemra, tocilizumab-anoh in both IV and SC formulation is approved to treat rheumatoid arthritis, pJIA, sJIA, COVID-19, and giant cell arteritis.
Weekly review: Changing atopic dermatology treatments, new puzzler, more
Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.
